Flagship Pioneering Merges Three Biotech Platforms Into Etcelera
Oct 29, 2026
Healthcare
EQT Life Sciences and Nextech Lead $183 Million Series C for Electra Therapeutics
Oct 22, 2025
Electra Therapeutics has raised $183 million in a Series C financing co-led by EQT Life Sciences and Nextech, with participation from Sanofi and other investors, to advance its immunology and cancer programs.
Electra Therapeutics has raised USD 183 million in Series C financing co-led by EQT Life Sciences and Nextech, with participation from Sanofi, HBM Healthcare Investments, Mubadala Capital, and existing investors, announced in a press release.
The funding will support a registrational Phase 2/3 clinical study of Electra’s lead program, ELA026, in secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory condition with no approved therapies. The study aims to confirm earlier Phase 1b results showing 100 percent survival at 8 weeks in frontline-treated patients.
Electra will also use the proceeds to expand ELA026 into hematologic cancers and to advance its second program, ELA822, which targets immune-mediated diseases. ELA026 has received FDA Breakthrough Therapy and EMA Priority Medicines designations for sHLH.
EQT Life Sciences partner Christoph Broja will join Electra’s board as an observer, supporting the company’s ongoing clinical and development initiatives.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly, AI Funding Brief or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 13 Bracco and Avicenna.AI win FDA clearance for AI that flags brain aneurysms on CT scans Nov 13 Zus Health raises $33 million to build the data layer for healthcare AI Nov 13 Google DeepMind releases AlphaGenome 2 to predict DNA variant effects in specific cell types Nov 13 Taiwan hospital accelerator T+ MedIC names AI ECG and CT screening tools as first winners Nov 13 Sheinbaum meets OpenAI president Greg Brockman on AI in Mexican healthcareMore from Funding
Nov 13 Polar DC adds Palistar financing as 2026 commitments pass EUR 1 billion Nov 13 Peter Sarlin's PostScriptum takes majority stake in Finnish AI deployment firm Brillian Nov 13 MISTT raises £5 million to build a space-and-time data layer for AI and autonomous systems Nov 13 Zus Health raises $33 million to build the data layer for healthcare AI Nov 12 Inveniam acquires Docugami, the document AI startup of XML pioneer Jean PaoliFree newsletter
AI Funding Brief
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
The Hackett Group
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Pathos AI Raises $237 Million at $3 Billion Valuation
Oct 23, 2026
Funding
EQT AI Infrastructure Fund Reaches $11.5 Billion in NAV
Oct 15, 2026
Data Centers
XRlabs Raises €7.48 Million for Surgical AI
Oct 20, 2026
Funding
Shield AI to Acquire Echodyne for $5.3 Billion
Nov 05, 2026
Funding
AstraZeneca and Oracle Partner on AI for Clinical Trials
Oct 20, 2026
Healthcare
Free, six days a week
Daily AI Brief: the AI news that matters, in your inbox.